The objective of this program is to expand and strengthen the capability of this institution to make meaningful scientific contributions in biomedical research. The proposed research program will involve studies from the parenchymal level to the whole animal. The projects are involved in studying the: (1) Controlled pretential oxidation of nucleosides; (2) Effect of selenium on hepatic glucose output; (3) Effect of new colchicine analogs on cancer cells; (4) In vitro antisickling activity of substituted benzoic acids; (5) Anti-inflammatory potency of derivatives of corticosteroids; (6) Antyi-cancer properties of new unsaturated ketonucleosides; (7) Effects of noncathecol Sympathomimetic drugs on glucose utilization in insulin dependent diabetes; (8) adrenal cortex during stress; (9) Tumor markers; (10) Neuroactive peptides; and (11) Synthesis and activity of some N-Aminotetrahydropyridines.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Minority Biomedical Research Support - MBRS (S06)
Project #
5S06RR008111-14
Application #
3513981
Study Section
General Research Support Program Advisory Committee (GRS)
Project Start
1978-06-01
Project End
1988-05-31
Budget Start
1985-06-01
Budget End
1986-05-31
Support Year
14
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Florida Agricultural and Mechanical University
Department
Type
Schools of Pharmacy
DUNS #
City
Tallahassee
State
FL
Country
United States
Zip Code
32307
Errahali, Younes J; Taka, Equar; Abonyo, Barack O et al. (2009) CCL26-targeted siRNA treatment of alveolar type II cells decreases expression of CCR3-binding chemokines and reduces eosinophil migration: implications in asthma therapy. J Interferon Cytokine Res 29:227-39
Taka, Equar; Errahali, Younes J; Abonyo, Barack O et al. (2008) Post-transcriptional silencing of CCR3 downregulates IL-4 stimulated release of eotaxin-3 (CCL26) and other CCR3 ligands in alveolar type II cells. Cytokine 44:342-51
You, Zhengqing; Lee, Henry Young (2006) New AZT conjugates as potent anti-HIV agents. Nucleosides Nucleotides Nucleic Acids 25:37-54
You, Zhengqing; Mian, A Moshin; Agarwal, Ram P et al. (2003) Synthesis, anti-HIV, and cytotoxic activity of new AZT conjugates of steroid acids. Nucleosides Nucleotides Nucleic Acids 22:2049-60
Badewa, A P; Heiman, A S (2003) Inhibition of CCL11, CCL24, and CCL26-induced degranulation in HL-60 eosinophilic cells by specific inhibitors of MEK1/MEK2, p38 MAP kinase, and PI 3-kinase. Immunopharmacol Immunotoxicol 25:145-57
Ko, Dong-Hoon; Heiman, Ann S; Hudson, Charles E et al. (2002) New steroidal antiinflammatory antedrugs: Methyl 3,20-dioxo-9 alpha-fluoro-11 beta,17 alpha,21-trihydroxy-1,4-pregnadiene-16 alpha-carboxylate and its 21-O-acyl derivatives. Steroids 67:211-9
Lee, Henry J; Cooperwood, John S; You, Zhengqing et al. (2002) Prodrug and antedrug: two diametrical approaches in designing safer drugs. Arch Pharm Res 25:111-36
Ko, D; Heiman, A S; Chen, M et al. (2000) New steroidal anti-inflammatory antedrugs: methyl 21-desoxy-21-chloro-11beta,17alpha-dihydroxy-3,20-dioxo-1, 4-pregnadiene-16alpha-carboxylate, methyl 21-desoxy-21-chloro-11beta-hydroxy-3,20-dioxo-1, 4-pregnadiene-16alpha-carboxylate, and their 9alpha-flu Steroids 65:210-8
Lee, H J; Ko, D H (1999) A novel approach to the discovery of non-systemic anti-inflammatory steroids;antedrug. Arch Pharm Res 22:279-87
Lee, H J; You, Z; Ko, D H et al. (1998) New steroidal antiinflammatory agents: prednisolone derivatives with an isoxazoline fusion at the 16- and 17-carbons and an alkyl carboxylate at the 16 alpha-position. Drugs Exp Clin Res 24:57-66

Showing the most recent 10 out of 34 publications